Download Cancer CD Antigen Inhibitors Market & Pipeline Insight2015 Report

Pharmaceutical companies are continuously looking for better therapeutic options to effectively cure and prevent various malignancies. Several options for cancer treatment are available belonging to various classes of molecules. Different types of cancer have different pathophysiological characteristics due to which distinctive approach is required for effective treatment. Several molecules have been discovered out of which CD antigens have been found to play an important role in cancer progression and proliferation. Investigators are trying to assign different functions to CD antigens by doing extensive research and development. Their role in cancer development has been noted due to which lots of progress would be observed in this segment. Most of the work has been done in cancer segment and pharmacological profiles are expected to be improved in coming years.

CD antigen cancer therapeutics have diverse design and target due to which they could be used for several malignancies. Presence of BiTEs, ADC, monoclonal antibodies and tri-functional antibodies for targeting different CD antigens has been commercialized. Next step is assumed to be the improvement in design as complexity at molecular levels makes it difficult to manufacture them in large quantities. This issue not only decreases the productivity but also increases the cost of production. Higher cost of end products limits the number of cancer patients choosing them as a part of their regular therapeutic regime. With the use of advanced technology it is expected that this issue would be overcome in coming years. Some of the progress could be observed in case of monoclonal antibodies and same scenario could be observed for other CD antigen cancer therapeutics in coming years.

Clinical trials are being instigated across the globe in order to extend their utilities in different malignancies. They are versatile in nature due to which they could be used as a part of combinatorial therapy along with monoclonal antibodies. Their utilities in different malignancies are also being studied but results of such clinical trials remains elusive. They have strong clinical pipeline due to which several products would be introduced in coming years. However, these products are at different stages of clinical pipeline and they may take long winding times as lots of experiments proving their safety and efficacy has to be done. With time more CD antigens are expected to be discovered and they would help in the increased market size. Commercial success of marketed CD antigen cancer therapeutics shows that they would be generating significant revenues in coming years.

CD antigen cancer market is expected to witness introduction of several products which will help the pharmaceutical companies to generate significant revenues. Increasing demand for better therapeutics, large unmet medical necessities and large numbers of cancer patient’s patient are expected to be responsible for the growth of this market segment. Increased funding in research and development along with utilization of advanced technology will also help in increasing their market shares across the globe. Numerous innovative CD antigen cancer therapeutics are at different stages of clinical trials which would increase their market shares. Despite these facts they have higher prices and their manufacturing is difficult but utilization of advanced technology along with streamlining of various processes are expected to overcome this barrier. In this way, future of CD antigen cancer therapeutics looks optimistic due to their superior pharmacological profiles.

CD Antigens Segments in Report:
CD3, CD4, CD9, CD11, CD19, CD20, CD22, CD26, CD27, CD28, CD29, CD33, CD37, CD40, CD44, CD45, CD47, CD52¸ CD55, CD56, CD66, CD70, CD74, CD80, CD95, CD98, CD100, CD117, CD135, CD137, CD152, CD200, CD223, CD227, CD246, CD248, CD274, CD276, CD279

“Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015” Report Highlight:

* Nomenclature & Classification of CD Antigens
* Mechanism of CD Antigen Cancer Therapeutics
* Cancer CD Antigen Therapy Market Overview
* Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
* Cancer CD Antigen Inhibitors Clinical Pipeline: 207 Drugs
* Marketed Cancer CD Antigen Inhibitors: 27 Drugs
* Majority of Cancer CD Antigen Inhibitors in Preclinical Phase: 70 Drugs
* Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 44 Drugs
* Cancer CD Antigens Clinical Pipeline is Represented in 52 Graphs & Charts

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-Cancer-CD-Antigen-Inhibitors-Market-&-Pipeline-Insight2015.php

1. Introduction to CD Antigens

2. Nomenclature & Classification of CD Antigens

3. Mechanism of CD Antigen Cancer Therapeutics

4. Cancer CD Antigen Therapy Market Overview
4.1 Current Scenario
4.2 Cancer CD Antigen Inhibitors Pipeline Overview

5. CD Antigen Cancer Market Dynamics
5.1 Favorable Market Parameters
5.2 Commercialization Challenges

6. CD Antigen Cancer Therapeutics Future Prospects

7. Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
7.1 Phase-I/II

8. Cancer CD3 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
8.1 Preclinical till Phase-II

9. Cancer CD4 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
9.1 Phase-II

10. Cancer CD9 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
10.1 Preclinical

11. Cancer CD11 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
11.1 Preclinical

12. Cancer CD19 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
12.1 Phase-I till Phase-II

13. Cancer CD20 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
13.1 Research till Phase-III
13.2 Marketed CD20 Antigen Inhibitors Drug Clinical Insight

14. Cancer CD22 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
14.1 Phase-II till Phase-III

15. Cancer CD26 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
15.1 Preclinical till Phase-I/II

16. Cancer CD27 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
16.1 Research till Phase-I/II

17. Cancer CD28 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
17.1 Preclinical

18. Cancer CD29 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
18.1 Preclinical

19. Cancer CD33 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
19.1 Phase-I till Phase-I/II
19.2 Marketed CD33 Antigen Inhibitors Drug Clinical Insight

20. Cancer CD37 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
20.1 Phase-I till Phase-II

21. Cancer CD38 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
21.1 Research till Preregistration

22. Cancer CD40 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
22.1 Phase-I

23. Cancer CD44 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
23.1 Preclinical

24. Cancer CD45 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
24.1 Preclinical till Phase-II

25. Cancer CD47 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
25.1 Preclinical till Phase-I

26. Cancer CD52 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
26.1 Research till Preclinical
26.2 Marketed CD52 Antigen Inhibitors Drug Clinical Insight

27. Cancer CD55 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
27.1 Preclinical till Phase-II

28. Cancer CD56 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
28.1 Preclinical till Phase-II

29. Cancer CD66 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
29.1 Preclinical till Phase-II

30. Cancer CD70 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
30.1 Phase-I

31. Cancer CD74 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
31.1 Preclinical till Phase-I/II

32. Cancer CD80 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
32.1 Preclinical till Phase-II

33. Cancer CD95 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
33.1 Preclinical

34. Cancer CD98 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
34.1 Phase-I

35. Cancer CD100 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
35.1 Phase-I

36. Cancer CD117 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
36.1 Preclinical till Phase-III
36.2 Marketed CD117 Antigen Inhibitors Drug Clinical Insight

37. Cancer CD135 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
37.1 Preclinical till Phase-III
37.2 Marketed CD135 Antigen Inhibitors Drug Clinical Insight

38. Cancer CD137 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
38.1 Preclinical

39. Cancer CD152 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
39.1 Marketed CD152 Antigen Inhibitors Drug Clinical Insight

40. Cancer CD200 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
40.1 Preclinical

41. Cancer CD223 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
41.1 Research till Phase-I

42. Cancer CD227 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
42.1 Phase-I till Phase-II

43. Cancer CD246 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
43.1 Preclinical till Phase-II
43.2 Marketed CD246 Antigen Inhibitors Drug Clinical Insight

44. Cancer CD248 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
44.1 Phase-II

45. Cancer CD274 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
45.1 Research till Phase-III
45.2 Marketed CD274 Antigen Inhibitors Drug Clinical Insight

46. Cancer CD276 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
46.1 Phase-I

47. Cancer CD279 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
47.1 Phase-I till Phase-II
47.2 Marketed CD279 Antigen Inhibitors Drug Clinical Insight

48. Multiple Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
48.1 Preclinical till Phase-III
48.2 Marketed Multiple CD Antigen Inhibitors Drug Clinical Insight

49. Discontinued & Suspended Cancer CD Antigen Inhibitors Drug Clinical Insight
49.1 No Development Reported
49.2 Discontinued
49.3 Market Withdrawal
49.4 Suspended

50. Competitive Landscape
50.1 Alexion Pharmaceuticals
50.2 ARIAD Pharmaceuticals
50.3 AryoGen Biopharma
50.4 AXXO
50.5 Bayer HealthCare
50.6 Biocad
50.7 Biogen
50.8 Biotecnol Inc.
50.9 Bristol-Myers Squibb
50.10 Chugai Pharmaceutical
50.11 Dr Reddy’s Laboratories
50.12 Eisai Co Ltd
50.13 Emergent BioSolutions
50.14 Genmab
50.15 ImmunoGen
50.16 Intas Biopharmaceuticals
50.17 MacroGenics
50.18 MedImmune
50.19 Merck
50.20 Novartis
50.21 Ono Pharmaceutical
50.22 Onyx Pharmaceuticals
50.23 Pfizer
50.24 PROBIOMED
50.25 Roche
50.26 UCB
50.27 Xencor

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Kuick Research
New Delhi - 110001
India
+91-11-47067990

This release was published on openPR.